AHR · American Healthcare REIT, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.09B | $1.88B | $1.67B | $1.41B | $1.12B | $67.79M |
| Cost of Revenue | $1.79B | $1.65B | $1.50B | $1.28B | $1.03B | $60.22M |
| Gross Profit | $300.98M | $229.91M | $166.43M | $130.63M | $93.74M | $7.57M |
| R&D | - | - | - | - | - | - |
| SG&A | $58.73M | $47.56M | $47.51M | $43.42M | $43.20M | $16.69M |
| Total Operating Expenses | $2.10B | $1.94B | $1.80B | $1.56B | $1.26B | $150.51M |
| D&A | $187.56M | $179.19M | $182.60M | $167.96M | $133.19M | $50.30M |
| Operating Income | $415.16M | $363.54M | $306.83M | $301.96M | $218.28M | ($18.94M) |
| Interest Expense | $85.78M | $127.73M | $163.19M | $105.96M | $80.94M | $19.95M |
| Income Tax | ($22.17M) | $1.71M | $663.0K | $586.0K | $956.0K | $0 |
| Net Income | $69.81M | ($37.81M) | ($71.47M) | ($81.30M) | ($47.79M) | ($18.06M) |
| EPS - Basic | $0.42 | ($0.29) | ($1.08) | ($1.24) | $0.01 | - |
| EPS - Diluted | $0.42 | ($0.29) | ($1.08) | ($1.24) | $0.01 | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $114.84M | $76.70M | $43.45M | $65.05M | $81.60M | $17.41M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | $18.84M | $19.48M | $19.47M | $19.77M | $24.67M | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | - | - | - | - | - | - |
| Total Assets | $5.43B | $4.49B | $4.58B | $4.79B | $4.58B | $1.09B |
| Current Liabilities | - | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $2.07B | $2.18B | $3.12B | $3.14B | $2.75B | $540.42M |
| Stockholders' Equity | $3.32B | $2.26B | $1.27B | $1.40B | $1.58B | $548.96M |
| Retained Earnings | ($1.56B) | ($1.46B) | ($1.28B) | ($1.14B) | ($951.30M) | ($185.05M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $294.44M | $176.09M | $98.53M | $147.77M | $17.91M | $35.49M |
| Investing Cash Flow | ($1.08B) | ($8.73M) | $9.40M | ($118.58M) | ($138.65M) | ($76.46M) |
| Financing Cash Flow | $817.24M | ($134.74M) | ($129.06M) | ($42.92M) | $94.11M | $43.24M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 14.4% | 12.2% | 10.0% | 9.3% | 8.3% | 11.2% |
| Operating margin | 19.8% | 19.3% | 18.4% | 21.4% | 19.4% | -27.9% |
| EBITDA margin | 28.8% | 28.8% | 29.3% | 33.3% | 31.3% | 46.3% |
| Net margin | 3.3% | -2.0% | -4.3% | -5.8% | -4.3% | -26.6% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 2.8% | 2.5% | 2.8% | 3.1% | 3.8% | 24.6% |
| Effective tax rate | -46.5% | - | - | - | - | - |
| Return on assets | 1.3% | -0.8% | -1.6% | -1.7% | -1.0% | -1.7% |
| Return on equity | 2.1% | -1.7% | -5.6% | -5.8% | -3.0% | -3.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 4.8x | 2.8x | 1.9x | 2.8x | 2.7x | -0.9x |
| Equity multiplier | 1.63 | 1.98 | 3.60 | 3.42 | 2.90 | 1.99 |
| Liabilities / Assets | 0.38 | 0.49 | 0.68 | 0.66 | 0.60 | 0.49 |
| Efficiency | ||||||
| Asset turnover | 0.39 | 0.42 | 0.36 | 0.30 | 0.25 | 0.06 |
| Inventory turnover | 95.21 | 84.92 | 77.15 | 64.81 | 41.76 | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 4d | 4d | 5d | 6d | 9d | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 112.0x | - | - | - | - | - |
| P / B | 2.4x | 1.6x | - | - | - | - |
| P / S | 3.7x | 2.0x | - | - | - | - |
| EV / EBITDA | 12.8x | 6.7x | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 11.2% | 12.9% | 18.2% | 25.6% | 1557.9% | -43.9% |
| Revenue CAGR (3y) | 14.0% | 18.8% | 190.9% | 127.0% | 137.0% | 45.9% |
| Revenue CAGR (5y) | 98.6% | 73.2% | 81.6% | 130.2% | 246.3% | - |
| Gross profit growth (YoY) | 30.9% | 38.1% | 27.4% | 39.4% | 1138.5% | -92.5% |
| Operating income growth (YoY) | 14.2% | 18.5% | 1.6% | 38.3% | - | -0.4% |
| Net income growth (YoY) | - | 47.1% | 12.1% | -70.1% | -164.7% | 3.8% |
| EPS growth (YoY) | - | 73.1% | 12.9% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 46.9% | 78.0% | -9.3% | -11.5% | 188.1% | -7.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.26B totalIntegrated Senior Health Campuses$1.76B · 78.0%
SHOP$330.57M · 14.6%
Outpatient Medical$126.08M · 5.6%
Triple Net Leased Properties$39.54M · 1.7%
Product / service
$1.46B totalResident Feesand Services$1.46B · 100.0%
Geographic
$2.26B totalUS$2.25B · 99.7%
Non Us$6.51M · 0.3%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- -Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Real Estate Investment Trusts
Comparing American Healthcare REIT against the 5 most active filers in the same SIC group.
Dividends
$1.00/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| Mar 31, 2026 | $0.2500 |
| Dec 31, 2025 | $0.2500 |
| Sep 30, 2025 | $0.2500 |
| Jun 30, 2025 | $0.2500 |
| Mar 31, 2025 | $0.2500 |
| Dec 31, 2024 | $0.2500 |
| Sep 20, 2024 | $0.2500 |
| Jun 27, 2024 | $0.2500 |
| Mar 27, 2024 | $0.2500 |